


European Reference Network

for rare or low prevalence complex diseases

Network

Vascular Diseases (VASCERN)



# Venous malformation

Final Approved Patient Pathway by the Vascular Anomalies (VASCA) Working Group – 29/04/2020

VASCERN VASCA working group Members: Miikka Vikkula, Laurence M. Boon, Andrea Diociaiuti, Veronika Dvorakova, May El Hachem, Nader Ghaffarpour, Alan Irvine, Friedrich Kapp, Kristiina Kyrklund, Jochen Rößler, Päivi Salminen, Caroline Van Den Bosch, Carine van der Vleuten, Leo Schultze Kool

Cooperating Guests: Anne Dompmartin, Eulalia Baselga Torres,

## Disclaimer

- This document is an opinion statement reflecting strategies put forward by experts and patient representatives involved in the Vascular Anomalies (VASCA) Rare Disease Working Group of VASCERN.
- It is preferable that patients be evaluated in a multidisciplinary center specialized in the diagnosis and management of vascular anomalies.
- This pathway is issued on 29/04/2020 and will be further validated and adjusted as needed.
- Responsibility for care of individual patients remains with the treating physician.



LEGEND:




https://vascern.eu

## **Suspected Venous Malformation**

### Histology :

- VM : dilated veins, sparse vascular smooth muscle cells
- GVM : veins surrounded by glomus cells
- Maffucci syndrome : spindle cell hemangioma
- VVM: clusters of venus-like channels, GLUT 1+

VM :Venous Malformations GVM: Glomuvenous Malformations VVM: Verrucous Venous Malformations



**Clinical** evaluation

Investigations

Treatment

Associated Genes





https://vascern.eu


#### Venous Malformation Diagnostic Work-Up continued For all types of VMs Α Sporadic Evaluate : Pain. aesthetic and Somatic TEK or **Sporadic Unifocal** Unifocal functional risk Venous IK3CA Majority of VMs Malformation No family history For all types of VMs Coagulation status (D Dimer, fibrinogen) MRI : Small bluish or skin coloured lesions, - if treatment is considered Sporadic Multifocal 2 involving skin, mucosa or sometimes - to anticipate complications Venous muscle Malformation - to characterize the VM: size and extent (e.g. muscles, joints, bones, organs) Somatic TEK В **Sporadic Multifocal** - if genital or perineal location MRI of the pelvis to rule out Less compressible internal vascular malformation Number increases with time One large VM at birth No family history Multiple small blue-to-purple "rubbery blebs" disseminated in entire body including GI tract, evolving over time **Blue Rubber Bleb** 3 Anaemia : Gl endoscopy Sometimes subcutaneous, mucosal or **Nevus Syndrome** hyperkeratotic lesions typically on palms (BRBN) and soles Anaemia Somatic TEK Hard bluish nodules Maffucci syndrome X Ray hands and feet : enchondroma Hand and foot deformities No coagulation abnormality Somatic IDH1 and 2 Single or multiple hyperkeratotic 5 Verrucous Venous Malformation (VVM) papules; can enlarge ; mainly on extremities (legs++) Genetics : Δ somatic = mutation Somatic MAP3K3 only in affected tissue (need biopsy) LEGEND: **Clinical** evaluation Associated Genes Investigations Treatment





https://vascern.eu

## Venous Malformation Diagnostic Work-Up continued








https://vascern.eu

### Venous Malformation Management/Treatment








https://vascern.eu

## Chronic Consumptive Coagulopathy Management



7







VASCERN, the European Reference Network on Rare Multisystemic Vascular Diseases, is dedicated to gathering the best expertise in Europe in order to provide accessible cross-border healthcare to patients with rare vascular diseases (an estimated 1.3 million concerned). These include arterial diseases (affecting aorta to small arteries), arterio-venous anomalies, vascular malformations, and lymphatic diseases.

VASCERN currently consists of 30 highly specialised multidisciplinary Healthcare Providers (HCPs) from 11 EU Member States and of various European Patient Organisations and is coordinated in Paris, France.

Through our 5 Rare Disease Working Groups (RDWGs) as well as several thematic WGs and the ePAG– European Patient Advocacy Group, we aim to improve care, promote best practices and guidelines, reinforce research, empower patients, provide training for healthcare professionals and realise the full potential of European cooperation for specialised healthcare by exploiting the latest innovations in medical science and health technologies.

More information available at: https://vascern.eu





Co-funded by the Health Programme of the European Union